The goal of this clinical trial is to learn if investigational agent LRK-4189 works to treat solid tumors in adults, with a focus on colorectal cancer. It will also learn about the safety of drug LRK-4189.
The main questions it aims to answer are:
Is LRK-4189, administered alone or in combination with standard chemotherapy regimens, safe and tolerable in patients with solid tumors?
Participants will:
* Take investigational agent LRK-4189 alone or in combination with standard chemotherapy regimens every day for up to 3 years. * Visit the clinic once every week for checkups and tests.
Willing and able to sign the study consent form and take part in all required study visits, tests, and procedures.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Have a locally advanced or metastatic cancer that cannot be removed with surgery and has gotten worse despite treatment.
Cancer can be measured on scans, such as CT or MRI.
Unable to swallow the study medication or your body cannot absorb it.
Have had a serious allergic reaction to LRK-4189 or any of its ingredients.
Have needed a fluid drainage procedure from the chest or abdomen within the past 6 weeks.
Have active cancer in the brain or spinal fluid, or brain tumors that require steroid treatment.
Sequential
LRK-4189 escalation
DrugLRK-4189 at various doses
LRK-4189 expansion
DrugLRK-4189 MTD
LRK-4189 optimization
DrugLRK-4189 2 distinct doses
Chemo
DrugStandard of care
Evaluation of treatment-related adverse events and/or toxicity, presented by dose, regimen and tumor type
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
